Cellectis Posts 544% Bigger Net Loss Despite Promising Trial Results

Cellectis (CLLS) reported Q4 2025 earnings on March 20, 2026, with results underscoring a sharp deterioration in profitability despite clinical progress. The company missed expectations as revenue fell 18.2% and net losses expanded. Management emphasized cash runway sustainability into late 2027 but provided no guidance adjustments, maintaining alignment with prior projections.

Revenue

The total revenue of Cellectis decreased by 18.2% to $10.40 million in 2025 Q4, down from $12.72 million in 2024 Q4.

Earnings/Net Income

Cellectis swung to a loss of $0.36 per share in 2025 Q4 from a profit of $0.08 per share in 2024 Q4 (543.2% negative change). Meanwhile, the company reported a net loss of $-26.32 million in 2025 Q4, reflecting a 544.4% deterioration from the net income of $5.92 million achieved in 2024 Q4. The earnings per share demonstrated a significant deterioration, underscoring poor performance in the quarter.

Price Action

The stock price of Cellectis has edged down 0.89% during the latest trading day, has edged down 2.34% during the most recent full trading week, and has plummeted 17.73% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Cellectis (CLLS) shares after a revenue drop quarter-over-quarter on the financial report release date and holding for 30 days resulted in poor performance. The strategy had a CAGR of -0.55% and an excess return of -50.75%, significantly underperforming the benchmark return of 48.57%. The strategy also had a high maximum drawdown of 76.01% and a Sharpe ratio of 0.00, indicating significant risk and losses.

CEO Commentary

André Choulika, Co-Founder, CEO & Director, highlighted Cellectis’s disciplined focus on advancing allogeneic CAR T therapies, emphasizing the 100% overall response rate in the target Phase II population for lasme-cel in B-cell acute lymphoblastic leukemia (B-ALL) and its role in bridging patients to transplants. He underscored the company’s strategic prioritization of clinical development, rigorous cash management, and partnerships, including collaborations with Servier, Allogene, and Iovance, to solidify its position as a leader in the allogeneic CAR T ecosystem. Choulika expressed optimism about 2026 milestones, including pivotal trial data for lasme-cel (Q4 2026) and eti-cel (2026), as well as the AstraZeneca partnership’s potential to drive innovation.

Guidance

Arthur Stril, CFO & Chief Business Officer, stated Cellectis’s cash, cash equivalents, and fixed-term deposits totaled $211 million as of December 31, 2025, providing sufficient liquidity to support pivotal trials into H2 2027.

Additional News

Cellectis announced encouraging Phase II interim results for lasme-cel, achieving a 100% overall response rate in B-ALL patients, and initiated pivotal trials with enrollment in North America and Europe. The company also reported 88% overall response rates for eti-cel in non-Hodgkin’s lymphoma, reinforcing its gene-editing platform’s potential. Strategic collaborations with AstraZeneca and expanded partnerships with Allogene and Iovance were highlighted as key drivers for future innovation. However, uncertainties persist regarding an arbitration ruling with Allogene, which could impact licensing and milestone payments.

Additional News

Cellectis emphasized its strong cash position, with $211 million in liquidity as of December 31, 2025, ensuring operational flexibility. The company also announced site openings for lasme-cel’s pivotal trial and expects interim data in Q4 2026. Management reiterated confidence in the allogeneic CAR T ecosystem, citing partnerships with industry leaders to accelerate therapeutic advancements. Challenges in the biotech sector, including competitive shifts in CD52 preconditioning strategies, were acknowledged as potential risks to clinical development timelines.